Can I read Expression of Bcl-2 in lung neuroendocrine tumours: comparison with p53 on EtoBox?
Expression of Bcl-2 in lung neuroendocrine tumours: comparison with p53 by Da-Gong Wang; Colin F. Johnston; James M. Sloan; Keith D. Buchanan is a Medicine article available to read on EtoBox.
What is Expression of Bcl-2 in lung neuroendocrine tumours: comparison with p53 about?
Several genetic aberrations have been implicated in the carcinogenesis of small cell lung carcinomas (SCLCs), including tumour suppressor gene p53 deletion and mutation and amplification of the myc family proto-oncogenes. However, their exact ontogeny and carcinogenesis remain unknown. There are no proven aetiological factors for lung carcinoid tumours. Recent evidence suggests that the genetic regulation of apoptosis is of critical importance during tumourigenesis and that oncogene and tumour suppressor genes can regulate the rate, or susceptibility, of cells to undergo apoptosis. In this study, the expression of Bcl-2 protein has been investigated in 77 primary lung neuroendocrine tumours, including 55 SCLCs and 22 carcinoid tumours, and compared with p53 expression. Of the 77 tumours studied, Bcl-2 immunoreactivity was present in 80 per cent of SCLCs, 43 per cent of typical, and 67 per cent of atypical carcinoid tumours with more than 10 per cent tumour cell positivity. Western and Northern blot analysis revealed that carcinoid tumours expressed the 26 kD protein and bcl-2 transcripts. Whereas 42 per cent of the SCLCs studied displayed p53 protein immunoreactivity in more than 1
Who reads Expression of Bcl-2 in lung neuroendocrine tumours: comparison with p53?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Da-Gong Wang; Colin F. Johnston; James M. Sloan; Keith D. Buchanan
- Publisher
- John Wiley and Sons; Wiley (John Wiley & Sons); John Wiley & Sons Inc.; Wiley (ISSN 0022-3417)
- Published
- 1998
- Language
- EN
- Field
- Medicine (Health Sciences)